ZNF398 Inhibitors
Chemical inhibitors of ZNF398 function by interfering with various signaling pathways and enzymatic activities that are crucial for the protein's role in transcriptional regulation. Palbociclib, a CDK4/6 inhibitor, can maintain the retinoblastoma protein in a hypo-phosphorylated state, which can influence ZNF398 activity due to the potential regulatory interactions between the pRb pathway and ZNF398 function. Similarly, MEK inhibitors such as U0126 and PD98059 can lead to a reduction in ERK activity, which can in turn inhibit the downstream effects on ZNF398 activity, as the protein's function can be impacted by ERK-mediated signaling. Another kinase inhibitor, LY294002, targets the PI3K/AKT pathway. By inhibiting this pathway, LY294002 can interfere with the signaling required for ZNF398's activity, as the PI3K/AKT pathway plays a role in various cellular processes including those that can regulate transcription factors. Rapamycin, which inhibits mTOR by binding to FKBP12, can alter the cellular environment necessary for ZNF398's function, given that mTOR is involved in regulating protein synthesis and other processes.
Other chemical inhibitors target different aspects of cellular signaling that can affect ZNF398. SP600125, by inhibiting JNK, can impede downstream transcriptional events required for ZNF398 to exert its function, as JNK influences transcription factors and stress responses. SB203580, a p38 MAP kinase inhibitor, can also prevent activation of downstream targets that are required for ZNF398's activity. Wortmannin, another PI3K inhibitor, similar to LY294002, can interrupt the necessary signaling for ZNF398 function. MG132, a proteasome inhibitor, can lead to an increase in the levels of proteins that may act as inhibitors or repressors of ZNF398. Staurosporine, with its broad-spectrum kinase inhibition, can prevent the phosphorylation required for ZNF398's activity. Lastly, KN-93, an inhibitor of CaMKII, can disrupt the calcium signaling pathways that may be necessary for the activation of ZNF398.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits cyclin-dependent kinases CDK4 and CDK6, ZNF398 is a transcription factor potentially regulated by the retinoblastoma protein (pRb) pathway which is, in turn, regulated by CDK4/6. Inhibition of CDK4/6 would prevent pRb phosphorylation, thus potentially maintaining ZNF398 in a hypo-phosphorylated state which could inhibit its transcriptional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream of ERK in the MAPK/ERK pathway. ZNF398 activity can be impacted by ERK-mediated signaling, thus inhibition of MEK1/2 and subsequent reduction in ERK activity can inhibit the downstream effects that would otherwise alter ZNF398's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits the PI3K/AKT pathway, which is involved in various cellular processes, including transcriptional regulation. ZNF398’s activity can be dependent on the proper functioning of this pathway. Inhibition of PI3K can therefore inhibit signaling required for ZNF398's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds FKBP12 and inhibits mTOR, a key kinase in the PI3K/AKT/mTOR pathway. As mTOR can regulate protein synthesis and other processes that may be necessary for ZNF398's functional activity, its inhibition by rapamycin can inhibit the cellular environment ZNF398 requires to function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. The JNK pathway can influence transcription factors and cellular stress responses. Inhibition of JNK could therefore inhibit downstream transcriptional events that are necessary for ZNF398 to exert its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase. p38 MAP kinase can affect transcription factors and cellular responses to stress. Inhibition of this kinase could prevent activation of downstream targets required for ZNF398's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, it can inhibit the AKT signaling pathway, which in turn can regulate various transcription factors and cellular processes, potentially including those involving ZNF398. Inhibition of this pathway can inhibit the necessary signaling for ZNF398 function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to an increase in cellular protein levels, which might include inhibitors or repressors of ZNF398. By preventing the degradation of such proteins, MG132 can inhibit the activity of ZNF398 by increasing the concentration of its natural inhibitors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which inhibits the activation of MAPK/ERK kinase. As ZNF398 may have its activity modulated by the MAPK/ERK pathway, inhibition of this pathway by PD98059 can inhibit the downstream effects that would otherwise alter ZNF398's function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. By inhibiting a wide range of kinases, it could inhibit those kinases that phosphorylate ZNF398 or its co-regulators, thereby inhibiting the phosphorylation state required for ZNF398's activity. | ||||||